🇪🇺 Zurzuvae in European Union

EMA authorised Zurzuvae on 30 October 2025

Marketing authorisation

EMA — authorised 30 October 2025

  • Application: EMEA/H/C/006488
  • Marketing authorisation holder: Biogen Netherlands B.V.
  • Local brand name: Zurzuvae
  • Indication: Zurzuvae is indicated for the treatment of postpartum depression (PPD) in adults following childbirth (see section 5.1). 
  • Status: approved

Read official source →

Zurzuvae in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in European Union

Frequently asked questions

Is Zurzuvae approved in European Union?

Yes. EMA authorised it on 30 October 2025.

Who is the marketing authorisation holder for Zurzuvae in European Union?

Biogen Netherlands B.V. holds the EU marketing authorisation.